Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background

Journal of Virological Methods

Volumn 237, Issue , 2016, Pages 192-199

  Hoffmann, Anja ^a   Schade, Dennis ^b   Kirchmair, Johannes ^c   Clement, Bernd ^d   Sauerbrei, Andreas ^a   Schmidtke, Michaela ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Antiviral; Drug design; Enzyme kinetics; Fitness; Resistance; Susceptibility

Indexed keywords

AMINO ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ENZYME INHIBITOR; SIALIDASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; GENE MUTATION; INFLUENZA; INFLUENZA A VIRUS; MDCK CELL LINE; NONHUMAN; PANDEMIC INFLUENZA; POINT MUTATION; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DOG; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HUMAN; INFLUENZA A VIRUS (H1N1); KINETICS; METABOLISM; MISSENSE MUTATION; MULTIDRUG RESISTANCE; MUTATION; PROCEDURES; REVERSE GENETICS;

AMINO ACID SUBSTITUTION; ANIMALS; DOGS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; REVERSE GENETICS; VIRAL PROTEINS; ZANAMIVIR;

EID: 84988836003     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2016.09.014     Document Type: Article

References (51)

1. Abed, Y., Goyette, N., Boivin, G., A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9 (2004), 577–581.
2. Abed, Y., Baz, M., Boivin, G., Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11 (2006), 971–976.
3. Abed, Y., Pizzorno, A., Bouhy, X., Rhéaume, C., Boivin, G., Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A (H1N1) pdm09 virus in vitro, in mice and in ferrets. J. Virol. 88 (2014), 1652–1658.
4. Arnold, K., Bordoli, L., Kopp, J., Schwede, T., The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2006), 195–201.
5. Baek, Y.H., Song, M.-S., Lee, E.-Y., Kim, Y.-i., Kim, E.-H., Park, S.-J., Park, K.J., Kwon, H.-i., Pascua, P.N.Q., Lim, G.-J., Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J. Virol. 89 (2015), 287–299.
6. Bauer, K., Dürrwald, R., Schlegel, M., Pfarr, K., Topf, D., Wiesener, N., Dahse, H.-M., Wutzler, P., Schmidtke, M., Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med. Microbiol. Immunol. 201 (2012), 61–72.
7. Bloom, J.D., Gong, L.I., Baltimore, D., Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328 (2010), 1272–1275.
8. Brookes, D.W., Miah, S., Lackenby, A., Hartgroves, L., Barclay, W.S., Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J. Antimicrob. Chemother. 66 (2010), 466–470.
9. Eshaghi, A., Patel, S.N., Sarabia, A., Higgins, R.R., Savchenko, A., Stojios, P.J., Li, Y., Bastien, N., Alexander, D.C., Low, D.E., Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg. Infect. Dis. 17 (2011), 1472–1474.
10. Garcia, V., Aris-Brosou, S., Comparative dynamics and distribution of influenza drug resistance acquisition to protein M2 and neuraminidase inhibitors. Mol. Biol. Evol. 31 (2014), 355–363.
11. Goto, H., Kawaoka, Y., A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 10224–10228.
12. Gubareva, L.V., Kaiser, L., Matrosovich, M.N., Soo-Hoo, Y., Hayden, F.G., Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001), 523–531.
13. Guex, N., Peitsch, M.C., Schwede, T., Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30 (2009), S162–S173.
14. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G., A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 6108–6113.
15. Hurt, A.C., Holien, J.K., Parker, M., Kelso, A., Barr, I.G., Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83 (2009), 10366–10373.
16. Hurt, A.C., Lowther, S., Middleton, D., Barr, I.G., Assessing the development of oseltamivir and zanamivir resistance in A (H5N1) influenza viruses using a ferret model. Antivir. Res. 87 (2010), 361–366.
17. Hurt, A.C., Chotpitayasunondh, T., Cox, N.J., Daniels, R., Fry, A.M., Gubareva, L.V., Hayden, F.G., Hui, D.S., Hungnes, O., Lackenby, A., Lim, W., Meijer, A., Penn, C., Tashiro, M., Uyeki, T.M., Zambon, M., Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12 (2012), 240–248.
18. Hurt, A.C., The epidemiology and spread of drug resistant human influenza viruses. Curr. Opin. Virol. 8 (2014), 22–29.
19. Kalbfuss, B., Knöchlein, A., Kröber, T., Reichl, U., Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36 (2008), 145–161.
20. Kim, C.U., Lew, W., Williams, M.A., Wu, H., Zhang, L., Chen, X., Escarpe, P.A., Mendel, D.B., Laver, W.G., Stevens, R.C., Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41 (1998), 2451–2460.
21. Lackenby, A., Hungnes, O., Dudman, S.G., Meijer, A., Paget, W.J., Hay, A.J., Zambon, M.C., Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill., 13, 2008.
22. Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen, K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y., Avian flu: isolation of drug-resistant H5N1 virus. Nature, 437, 2005, 1108.
23. Li, W., Escarpe, P.A., Eisenberg, E.J., Cundy, K.C., Sweet, C., Jakeman, K.J., Merson, J., Lew, W., Williams, M., Zhang, L., Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998), 647–653.
24. Li, Q., Qi, J., Zhang, W., Vavricka, C.J., Shi, Y., Wei, J., Feng, E., Shen, J., Chen, J., Liu, D., He, J., Yan, J., Liu, H., Jiang, H., Teng, M., Li, X., Gao, G.F., The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 17 (2010), 1266–1268.
25. Little, K., Leang, S.K., Butler, J., Baas, C., Harrower, B., Mosse, J., Barr, I.G., Hurt, A.C., Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill., 20, 2015.
26. Marathe, B.M., Leveque, V., Klumpp, K., Webster, R.G., Govorkova, E.A., Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One, 8, 2013, e71401.
27. McKimm-Breschkin, J.L., Williams, J., Barrett, S., Jachno, K., McDonald, M., Mohr, P.G., Saito, T., Tashiro, M., Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J. Antimicrob. Chemother. 68 (2013), 2210–2221.
28. McKimm-Breschkin, J.L., Williams, J., Barrett, S., Jachno, K., McDonald, M., Mohr, P.G., Saito, T., Tashiro, M., Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J. Antimicrob. Chemother. 68 (2013), 2210–2221.
29. Monto, A.S., McKimm-Breschkin, J.L., Macken, C., Hampson, A.W., Hay, A., Klimov, A., Tashiro, M., Webster, R.G., Aymard, M., Hayden, F.G., Zambon, M., Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006), 2395–2402.
30. Mooney, C.A., Johnson, S.A., t Hart, P., Quarles van Ufford, L., de Haan, C.A., Moret, E.E., Martin, N.I., Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors. J. Med. Chem. 57 (2014), 3154–3160.
31. Nguyen, H.T., Sheu, T.G., Mishin, V.P., Klimov, A.I., Gubareva, L.V., Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54 (2010), 3671–3677.
32. Nguyen, H.T., Fry, A.M., Gubareva, L.V., Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17 (2012), 159–173.
33. Okomo-Adhiambo, M., Nguyen, H.T., Sleeman, K., Sheu, T.G., Deyde, V.M., Garten, R.J., Xu, X., Shaw, M.W., Klimov, A.I., Gubareva, L.V., Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85 (2010), 381–388.
34. Okomo-Adhiambo, M., Sheu, T.G., Gubareva, L.V., Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir. Viruses 7:Suppl. 1 (2012), 44–49.
35. Rath, B., von Kleist, M., Tief, F., Karsch, K., Tuerk, E., Muehlhans, S., Louis, F., Skopnik, H., Schweiger, B., Duwe, S., Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses. Pediatr. Infect. Dis. J. 31 (2012), 899–905.
36. Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoint. Am. J. Hyg. 27 (1938), 493–497.
37. Richter, M., Schumann, L., Walther, E., Hoffmann, A., Braun, H., Grienke, U., Rollinger, J.M., Von Grafenstein, S., Liedl, K.R., Kirchmair, J., Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors. Future Virol. 10 (2015), 77–88.
38. Schade, D., Kotthaus, J., Riebling, L., Kotthaus, J., Muller-Fielitz, H., Raasch, W., Koch, O., Seidel, N., Schmidtke, M., Clement, B., Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. J. Med. Chem. 57 (2014), 759–769.
39. Schade, D., Kotthaus, J., Riebling, L., Kotthaus, J., Muller-Fielitz, H., Raasch, W., Hoffmann, A., Schmidtke, M., Clement, B., Zanamivir amidoxime- and N-hydroxyguanidine-based prodrug approaches to tackle poor oral bioavailability. J. Pharm. Sci. 104 (2015), 3208–3219.
40. Sheu, T.G., Deyde, V.M., Okomo-Adhiambo, M., Garten, R.J., Xu, X., Bright, R.A., Butler, E.N., Wallis, T.R., Klimov, A.I., Gubareva, L.V., Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52 (2008), 3284–3292.
41. van der Vries, E., Stelma, F.F., Boucher, C.A., Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363 (2010), 1381–1382.
42. van der Vries, E., Collins, P.J., Vachieri, S.G., Xiong, X., Liu, J., Walker, P.A., Haire, L.F., Hay, A.J., Schutten, M., Osterhaus, A.D., Martin, S.R., Boucher, C.A., Skehel, J.J., Gamblin, S.J., H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog., 8, 2012, e1002914.
43. von Itzstein, M., The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6 (2007), 967–974.
44. Webster, R.G., Govorkova, E.A., Continuing challenges in influenza. Ann. N. Y. Acad. Sci. 1323 (2014), 115–139.
45. WHO, Clinical features of severe cases of pandemic influenza - Pandemic (H1N1) 2009 briefing note 13. World Health Organization Global Alert and Response. 2009 Web. Jul 2016, http://www.who.int/csr/disease/swineflu/notes/h1n1_clinical_features_20091016/en/.
46. WHO, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility—Geneva, November 2011 and June 2012;. Wkly. Epidemiol. Rec. 87:39 (2012), 369–374 Web. Jul 2016, http://www.who.int/wer/2012/wer8739.pdf.
47. WHO, World Health Organization Regional Office for Europe recommendations on influenza vaccination during the 2014/2015 winter season. 2014 Web. Jul 2016, http://www.euro.who.int/__data/assets/pdf_file/0006/259404/WHO-Regional-Office-for-Europe-recommendations-on-influenza-vaccination-during-the-2014-2015-winter-season-Eng.pdf?ua=1.
48. WHO, online. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitor (NAI), Web. Jul 2016, http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_phenotyping/en/.
49. Woods, J.M., Bethell, R.C., Coates, J.A., Healy, N., Hiscox, S.A., Pearson, B.A., Ryan, D.M., Ticehurst, J., Tilling, J., Walcott, S.M., et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37 (1993), 1473–1479.
50. Xu, X., Zhu, X., Dwek, R.A., Stevens, J., Wilson, I.A., Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 82 (2008), 10493–10501.
51. Yen, H.L., Ilyushina, N.A., Salomon, R., Hoffmann, E., Webster, R.G., Govorkova, E.A., Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007), 12418–12426.